Table 10

Any malignancy adverse events

Adverse Event

n/patient-years of exposure (Incidence Rate per 100 Patient-years^†)

Sitagliptin

100 mg

Non-exposed

Difference between Sitagliptin and

Non-exposed (95% CI)*

Any malignancy

46/4690 (1.0)

40/3930 (1.0)

-0.0 (-0.5, 0.4)

n = number of patients with ≥ 1 occurrence of the endpoint; CI = confidence interval;

^†100 * (number of patients with ≥ 1 event/person years of follow-up time).

* Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

Williams-Herman et al. BMC Endocrine Disorders 2010 10:7   doi:10.1186/1472-6823-10-7